Last reviewed · How we verify
AcSDKP-NH2 inuline
AcSDKP-NH2 inuline is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.
At a glance
| Generic name | AcSDKP-NH2 inuline |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AcSDKP-NH2 inuline CI brief — competitive landscape report
- AcSDKP-NH2 inuline updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about AcSDKP-NH2 inuline
What is AcSDKP-NH2 inuline?
AcSDKP-NH2 inuline is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes AcSDKP-NH2 inuline?
AcSDKP-NH2 inuline is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
What development phase is AcSDKP-NH2 inuline in?
AcSDKP-NH2 inuline is in Phase 1.
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Compare: AcSDKP-NH2 inuline vs similar drugs
- Pricing: AcSDKP-NH2 inuline cost, discount & access